Stiripentol
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Stiripentol. Stiripentol is a GABAA receptor modulator, It increases the serum levels of Clobazam and Valproate. Fully referenced neurology checklist.
Mode of action
- Stiripentol is a GABAA receptor modulator
- It increases the serum levels of Clobazam and Valproate
Indications
Locked: subscribe to see this section.
Dosing
Locked: subscribe to see this section.
Neuropsychiatric side effects
Locked: subscribe to see this section.
Systemic side effects
Locked: subscribe to see this section.
References
- Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia 2013; 54:1595-1604.
- Jogamoto T, Yamamoto Y, Fukuda M, et al. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy Res 2016; 130:7-12.
- Inoue Y, Ohtsuka Y; STP-1 Study Group. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan. Epilepsy Res 2015; 113:90-97.
- Trivisano M, Specchio N, Vigevano F. Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. Eur J Paediatr Neurol 2015; 19:248-250.
- Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand 2015; 132:435-439.
